Synapse - David Spriggs

Search Within

David R Spriggs

Results (81)

CA125 level as a predictor of progression-free survival and overall survival in ovarian cancer patients with surgically defined disease status prior to the initiation of intraperitoneal consolidation therapy

Journal Article

Juretzka, M. M.; Barakat, R. R.; Chi, D. S.; Iasonos, A.; Dupont, J.; Abu-Rustum, N. R.; Poynor, E. A.; Aghajanian, C.; Spriggs, D.; Hensley, M. L.; more...
Gynecologic Oncology (2007)

Fulltext@MSK | Save

A phase I trial of BMS-247550 (NSC# 710428) and gemcitabine in patients with advanced solid tumors

Journal Article

Hensley, M. L.; Dizon, D.; Derosa, F.; Venkatraman, E.; Sabbatini, P.; Chi, D. S.; Dupont, J.; Colevas, A. D.; Spriggs, D.; Aghajanian, C.
Investigational New Drugs (2007)

Fulltext@MSK | Save

Preoperative serum YKL-40 is a marker for detection and prognosis of endometrial cancer

Journal Article

Diefenbach, C. S. M.; Shah, Z.; Iasonos, A.; Barakat, R. R.; Levine, D. A.; Aghajanian, C.; Sabbatini, P.; Hensley, M. L.; Konner, J.; Tew, W.; more...
Gynecologic Oncology (2007)

Fulltext@MSK | Save

Ovarian cancer

Book Section

Sonoda, Y.; Spriggs, D.
In Chang, A. E.; Hayes, D. F.; Pass, H. I.; Stone, R. M.; Ganz, P. A.; Kinsella, T. J.; Schiller, J. H.; Strecher, V. J. (Eds.) Oncology: An Evidence-Based Approach (2006)

Fulltext@MSK | Save

Paclitaxel and carboplatin in the adjuvant treatment of patients with high-risk stage III and IV endometrial cancer: A retrospective study

Journal Article

Sovak, M. A.; Hensley, M. L.; Dupont, J.; Ishill, N.; Alektiar, K. M.; Abu Rustum, N.; Barakat, R.; Chi, D. S.; Sabbatini, P.; Spriggs, D. R.; more...
Gynecologic Oncology (2006)

Fulltext@MSK | Save

Phase II study of tirapazamine plus cisplatin in patients with advanced or recurrent cervical cancer

Journal Article

Maluf, F. C.; Leiser, A. L.; Aghajanian, C.; Sabbatini, P.; Pezzulli, S.; Chi, D. S.; Wolf, J. K.; Levenback, C.; Loh, E.; Spriggs, D. R.
International Journal of Gynecological Cancer (2006)

Fulltext@MSK | Save

Phase I/II study of weekly paclitaxel plus carboplatin and gemcitabine as first-line treatment of advanced-stage ovarian cancer: Pathologic complete response and longitudinal assessment of impact on cognitive functioning

Journal Article

Hensley, M. L.; Correa, D. D.; Thaler, H.; Wilton, A.; Venkatraman, E.; Sabbatini, P.; Chi, D. S.; Dupont, J.; Spriggs, D.; Aghajanian, C.
Gynecologic Oncology (2006)

Fulltext@MSK | Save

Paclitaxel and carboplatin (TP) for treatment of advanced or recurrent endometrial cancer: A retrospective study

Meeting Abstract

Sovak, M. A.; Chuai, S.; Anderson, S.; Barakat, R.; Dupont, J.; Hensley, M. L.; Sabbatini, P.; Spriggs, D. R.; Aghajanian, C.
Journal of Clinical Oncology (2005)

Fulltext@MSK | Save

Paclitaxel, carboplatin plus gemcitabine (PCG) as first-line treatment for advanced epithelial ovarian cancer (EOC): Pathologic complete response (pCR) and impact on cognitive functioning

Meeting Abstract

Hensley, M. L.; Correa, D.; Thaler, H.; Wilton, A.; Venkatraman, E.; Sabbatini, P.; Chi, D.; Spriggs, D.; Aghajanian, C.
Journal of Clinical Oncology (2005)

Fulltext@MSK | Save

A phase III randomized trial of cisplatin and paclitaxel administered by either 24 hour or 96 hour infusion in patients with selected stage III or stage IV epithelial ovarian cancer (GOG 162)

Meeting Abstract

Spriggs, D. R.; Brady, M.; Rubin, S.; Hanley, M.; Copeland, L. J.; Clarke-Pearson, D.; Burger, R.
Journal of Clinical Oncology (2004)

Fulltext@MSK | Save